The pharma manufacturing industry is seeing a surge in demand for high-potency active pharmaceutical ingredients (HPAPIs) fuelled by growth in the biopharma sector and the oncological and immune-suppressant fields. Michael Avraam, ChargePoint Technology, explores drug manufacturers’ need to develop increasingly innovative containment strategies as a result, in order to meet the high-potency handling requirements. As these containment strategies evolve, so too does the role of containment verification and monitoring technology.

Comments are closed.

%d bloggers like this: